FDA Updates Rules for Medicated Animal Feed Stability Tests
Published Date: 4/16/2026
Notice
Summary
The FDA just released a draft update on how to test the stability of medicated premixes—those are the special mixes added to animal feed to keep pets and farm animals healthy. This update affects companies making these products by giving clearer, improved testing rules to make sure the mixes stay effective. If you’re in the business, get your comments in by June 15, 2026, or risk missing out on shaping the final rules!
Analyzed Economic Effects
5 provisions identified: 4 benefits, 0 costs, 1 mixed.
Updated Stability Testing Rules
If you make medicated premixes for animal feed, the FDA released a draft revision that contains updated recommendations for how to test the stability of those premixes and how to show they stay stable in the intended medicated feed. This is a draft guidance (VICH GL8(R1)) the FDA is proposing for industry use.
Opportunity to Comment by June 15, 2026
If you or your company want to influence the final guidance, you must submit comments by June 15, 2026 for the Agency to consider them before it begins work on the final version. You can submit comments electronically at https://www.regulations.gov or as written/paper submissions to the Dockets Management Staff.
Draft Guidance Is Non‑Binding
The draft guidance represents the FDA's current thinking but does not establish any rights and is not binding on FDA or the public. You may use an alternative approach if it satisfies the applicable statutes and regulations.
No New Paperwork Collections
The FDA states the draft guidance contains no new collection of information, but it references previously approved information collections under OMB control numbers 0910-0032 and 0910-0117. This means the draft itself does not add new paperwork requirements.
FDA Will Consider Cost Comments
As FDA develops the final guidance, it will consider comments on costs or cost savings the guidance may generate, consistent with Executive Order 14192. Stakeholders can submit cost-related comments for FDA to review during finalization.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-07418, Agency Information Collection Activities: Notice of Request for Reinstatement of a Previously Approved Information Collection
The Federal Highway Administration wants to bring back a previously approved info collection for the Dwight David Eisenhower Transportation Fellowship Program. This affects colleges running the local fellowship competition and helps attract and grow top transportation talent. Comments on this plan are open until May 18, 2026, with no new costs expected.
Next: 2026-07420, Publishing.com, LLC, Christian Mikkelsen, and Rasmus Mikkelsen; Analysis of Proposed Consent Order To Aid Public Comment
Publishing.com, LLC and the Mikkelsen brothers are facing charges for unfair or deceptive business practices. They’ve agreed to stop these actions under a proposed deal, and the public has until May 18, 2026, to share their thoughts. This means changes for the company and no money penalties are mentioned yet, but everyone’s watching closely!